- Home
- SD vs CMPX Comparison
SD vs CMPX Comparison
Compare SD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | CMPX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 408.8M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SD | CMPX |
|---|---|---|
| Price | $14.63 | $2.00 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $15.00 | $14.57 |
| AVG Volume (30 Days) | 251.6K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | $934.41 |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.10 | $1.61 |
| 52 Week High | $18.45 | $6.88 |
Technical Indicators
Market Signals| Indicator | SD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 38.72 |
| Support Level | $14.37 | $1.88 |
| Resistance Level | $15.71 | $2.08 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 71.14 | 1.96 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.